Issues
-
Cover Image
Cover Image
Chemotherapeutic elimination (green) of the tumor is a complex challenge. Mathematical modeling of tumor-immune interactions reveals that optimal therapy, which may initially seem black and white, requires delicate navigation through a complex multidimensional landscape personalized to each patient. Cytotoxic efficacy (purple) must be balanced with supporting patient antitumor immune responses stimulated by lymphodepletion (blue). Optimal therapy treads an intermediate path (gold) that maintains dosing within a maximally effective window. The authors acknowledge the help of Dr. Chandler D. Gatenbee who provided coding expertise on the coloring for the image. For details, see article by Park and colleagues on page 5302. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Research
Table of Contents
Breaking Insights
Reviews
Cancer Research Highlights
Priority Report
miR-221 Targets QKI to Enhance the Tumorigenic Capacity of Human Colorectal Cancer Stem Cells
Genome and Epigenome
Metabolism and Chemical Biology
Targeting Myeloperoxidase Disrupts Mitochondrial Redox Balance and Overcomes Cytarabine Resistance in Human Acute Myeloid Leukemia
Molecular Cell Biology
CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival
Tumor Biology and Immunology
Prolactin Promotes Fibrosis and Pancreatic Cancer Progression
Translational Science
Meflin-Positive Cancer-Associated Fibroblasts Inhibit Pancreatic Carcinogenesis
In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis
Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFNβ-Driven Antitumor Immunity
Convergence and Technologies
Population and Prevention Science
High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Cancer: Results from the Ovarian Cancer Cohort Consortium
Resource Report
Correction
Correction: An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors
Editor’s Note
Retraction
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.